With the high season for pharmaceuticals and the Double 11, pharmaceutical companies saw their November revenue soar, with 12 companies including Yung Zip Chemical, TTY Biopharm, Synmosa Biopharma, Grape King Bio, ShinyBrands, Ever Supreme Biotechnology, United Orthopedic, and Onyx Healthcare hitting new highs.

Among the pharmaceutical stocks, API supplier Yung Zip's products focus on antipyretic, analgesic, anti-inflammatory, herpes treatment and antihypertensive agents, etc. This year's revenue increased by nearly 80% in November due to the concentration of orders from customers and the growth of merged subsidiaries. 

The addition of an adjuvanted flu vaccine for people over 65 years of age is expected to be certified by the end of the first quarter next year, and anti-mycotic products will also be launched in the US.

Ever Supreme Biotechnology, which has had nine consecutive months of positive revenue growth, is a big winner in cellular therapy, with more than 500 patients currently enrolled and a patient schedule until the third quarter of next year. The company is already active in the CAR-T field and is planning to re-license Phase I when it is completed.

In the beauty and health care group, Grape King's revenue in the first 11 months was 9.281 billion, up 6.15% year-on-year. The company is optimistic that its annual revenue will easily reach the 10 billion mark and its profit will challenge a capitalization.

ShinyBrands benefited from its iQueen shopping platform, which reported good results on the Double 11, with nearly 150,000 visitors to its website throughout the day on 11/11. The cumulative number of new members and transactions increased by double digits compared to the same period last year.

Among the medical materials group, United Orthopedic' surgical volume has returned to normal due to the lifting of the global epidemic, and the company has safe stocks to supply the market with urgent orders. The outlook for the next year is cautiously optimistic as supply and demand are expected to return to normal and new products are expected to contribute.

With 10 consecutive months of revenue growth of more than 10%, Onyx Healthcare has developed its medical imaging artificial intelligence platform ACCEL-JS1000 through NVIDIA's platform, which offers an 8x improvement in AI performance and is expected to be launched in the fourth quarter.